RECCE 529 / The Peter Doherty Institute for Infection and Immunity, Recce Pharma, Path BioAnalytics - LARVOL DELTA

Recce Pharmaceuticals Completes Capital Raising of $27.95 Million (GlobeNewswire) - "Recce Pharmaceuticals Ltd...is pleased to announce it has raised A$27,950,000 (before costs)...that will result in 21,500,000 full paid ordinary shares being issued at A$1.30 per share (Placement)....Additional support by the Australian Government’s 43.5% R&D rebate on R&D applicable activities, ensures the Company is fully funded to complete its Phase I human clinical trial....Funds will also be used to support regulatory submissions and general corporate purposes."

Financing • Infectious Disease • Novel Coronavirus Disease